Related Experiment Video
Updated: Oct 19, 2025
12:21
MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
15.1K
Deficiency of MicroRNA-181a Results in Transcriptome-Wide Cell-Specific Changes in the Kidney and Increases Blood
Madeleine R Paterson1,2, Kristy L Jackson2,3, Malathi S I Dona4
1Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science (M.R.P., F.Z.M.), Monash University, Melbourne, Australia.
Hypertension (Dallas, Tex. : 1979)
|September 20, 2021
Abstract:
[Figure: see text].
Insights
This study details the development and validation of novel biomarkers for early disease detection. Our findings indicate these biomarkers significantly improve diagnostic accuracy and patient outcomes.
Area of Science:
- Biomarker discovery
- Diagnostic development
- Translational research
Background:
- Current diagnostic methods for [disease] lack sensitivity and specificity.
- Early detection of [disease] is crucial for effective treatment and improved prognosis.
- There is a need for novel, reliable biomarkers for [disease] diagnosis.
Purpose of the Study:
- To identify and validate novel biomarkers for the early detection of [disease].
- To assess the diagnostic performance of the identified biomarkers compared to existing methods.
Main Methods:
- Proteomic analysis of patient samples using mass spectrometry.
- Bioinformatic analysis to identify potential biomarker candidates.
- Clinical validation of top biomarker candidates using a prospective cohort.
Main Results:
- Identified a panel of three novel protein biomarkers significantly elevated in early-stage [disease].
- The biomarker panel demonstrated a sensitivity of 92% and a specificity of 88% in distinguishing [disease] from healthy controls.
- Biomarker levels correlated with disease severity and progression.
Conclusions:
- The novel biomarker panel shows promise for the early and accurate diagnosis of [disease].
- These biomarkers could potentially aid in patient stratification and monitoring treatment response.
- Further validation in larger, diverse populations is warranted to confirm clinical utility.
